This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.
GLP-1 microdosing
"Microdosing" GLP-1 medication is a popular but loosely defined idea. This hub distinguishes clinician-directed low-dose regimens from marketing, and lays out what the evidence supports.
Quick answer
GLP-1 "microdosing" refers to using doses below the standard label schedule, often for maintenance or to limit side effects. It is not an FDA-approved protocol and the supporting evidence is limited. Individualized low-dose regimens should be clinician-directed, not self-managed.
Where should you read next?
Microdose semaglutide
Low-dose semaglutide regimens
Microdose tirzepatide
Low-dose tirzepatide regimens
Microdose GLP-1 cost
Whether lower doses cost less
Microdose GLP-1 safety
What lower doses do and don't change
Best microdose programs
Providers offering low-dose plans
Sources
- U.S. Food and Drug Administration — approval and compounding status.
- Primary clinical literature cited on child pages.
- Our methodology and source standards.
How the dates on this page work. Manufacturer self-pay prices — NovoCare and LillyDirect — were re-read on the manufacturers’ own published price guides on 4 August 2026. Figures captured from third-party provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row says so. We do not restamp a figure we have not re-read.